Menu
Not yet recruiting NCT07713212

Combined Fractional CO₂ Laser and Topical Corticosteroid Versus Topical Corticosteroid Only in the Treatment of Palmoplantar Psoriasis

Phase IV Interventional Psoriasis

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Fractional CO2 laser assisted drug delivery, Topical Corticosteroid (TCS).
Who it may be relevant to
Registry conditions: Psoriasis. Basic parameters: 18 years — 60 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Egypt
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Comparative Study of the Efficacy and Safety of Combined Fractional CO₂ Laser and Topical Corticosteroid Versus Topical Corticosteroid Only in the Treatment of Palmoplantar Psoriasis: A Pilot Randomized Controlled Clinical Trial

Overview

To assess whether adding fractional laser to topical corticosteroid improves treatment outcomes in palmoplanter psoriasis compared to topical corticosteroid alone.

Detailed description

· To evaluate and compare the reduction in disease severity of palmoplantar psoriasis using the Palmoplantar Psoriasis Area and Severity Index (PPPASI) in both treatment groups

Interventions

  • Device Fractional CO2 laser assisted drug delivery
    Sessions of fractional CO2 every 4 weeks with application of topical steroids
  • Drug Topical Corticosteroid (TCS)
    Daily application of topical corticosteroids on palmoplantar psoriasis

Primary outcome measures

  • Improvement in Palmoplantar Psoriasis Severity Index (ppPASI) by topical corticosteroids only vs fractional CO₂ laser-assisted delivery of topical corticosteroids [Time frame: 3 month]
Secondary outcome measures (1)
  • Physician Global Assessment (PGA) [Time frame: 3 months]

Eligibility criteria

Inclusion criteria

  • Adults aged ≥18 years
  • Stable psoriasis
  • Confirmed cases of palmoplantar psoriasis (with or without psoriasis elsewhere) dermoscopically(Hand \_held dermoscopy) and histopathologically if required.
  • Willingness to comply with treatment and follow-up
  • Written informed consent obtained

Exclusion criteria

  • Other palmoplantar dermatoses (eczema, tinea, keratoderma)
  • Generlized Pustular psoriasis
  • Erythrodermic psoriasis
  • Use of:
  • Systemic antipsoriatic therapy within 3 months
  • Biologic therapy within 12 weeks
  • Topical treatment on palms/soles within 2 weeks
  • Pregnancy or lactation
  • History of photosensitivity disorders

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Treatment

Study locations

Egypt · 1 center
  • Cairo University — Cairo

Identifiers

NCT: NCT07713212 · MS-124-2026

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗